AdBio partners (formerly Advent France Biotechnology) is a Paris-based venture capital firm specialized in early-stage investments in the most promising life sciences startups across Europe, focusing on breakthrough medical discoveries in areas such as oncology, immunology, and rare diseases.
32% of their portfolio is in Biotech & Life Sciences. Their most common stage is seed (50% of deals).
Portfolio
16
Fund Size
$102M
Top Stage
Seed
Last 12 Mo
2
Team
Clément BERTHOLET
Managing Partner
Aksana LABOKHA
Venture Partner
Didier LECONTE
Venture Partner
Geoffroy DE RIBAINS
Venture Partner
Jacques DUMAS
Venture Partner
Josselin CARADEC
Venture Partner (Barcelona)
Laurence DE SCHOULEPNIKOFF
Venture Partner
Mounia AZZI
Partner
Patrick BURGERMEISTER
Venture Partner
Adrien CLAVAIROLY
Principal
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Tenpoint Therapeutics | Series B | — | Jan 2026 |
 Arthex Biotech | Series B | $87M | Sep 2025 |
 Augustine Therapeutics | Series A | — | Mar 2025 |
| AAndzonBio1 | Seed | — | Oct 2024 |
 Astraveus | Seed | — | Jun 2023 |
| AAstraveus | Seed | — | Jun 2023 |
| AAnoat Therapeutics | Seed | — | Jun 2023 |
| CCalida Therapeutics | Seed | $2M | Apr 2023 |
| TTridek-One | Unknown | — | Jan 2023 |
 DiogenX | Series A | — | Jan 2023 |
| Astraveus | Seed | — | Jan 2023 |
| AAstraveus | Seed | — | Jan 2023 |
 Tridek-One | Series A | — | Sep 2022 |
| TTridek-One | Unknown | — | Sep 2022 |
| IIntegra Therapeutics | Seed | — | Mar 2022 |
| IIntegra Therapeutics | Seed | — | Dec 2021 |
| TTridek-One | Unknown | — | Jun 2019 |
| TTridek-One | Unknown | — | Jan 2019 |
| UUnivercells SA | Series D | — | — |
| TThabor Therapeutics | Seed | — | — |
| UUnivercells | Series D | — | — |
| OOrikine Bio | Seed | — | — |
Top Co-Investors
Last updated: 8 September 2026